Genesis Research LLC
About Genesis Research LLC
Company overview
Genesis Research LLC is a privately-held research and consulting company operating in the fields of biotechnology, pharmaceuticals, and life sciences. They offered a wide range of services aimed at assisting pharmaceutical and biotech companies, healthcare organizations, and other stakeholders in the life sciences sector. Their core services might have included: Research and Development (R&D) Consulting: Providing strategic advice and support for drug discovery, clinical trial design, regulatory affairs, and product development. Market Research and Analysis: Conducting market intelligence, competitor analysis, and market forecasting to help clients make informed business decisions. Health Economics and Outcomes Research (HEOR): Analyzing the economic and clinical impact of healthcare interventions and treatments. Real-World Evidence (RWE) Generation: Collecting and analyzing data from real-world settings to generate evidence on treatment effectiveness and safety. Market Access and Pricing Strategy: Assisting in navigating reimbursement policies and designing pricing strategies for new therapies. Health Technology Assessment (HTA): Supporting the evaluation of new medical technologies for their cost-effectiveness and potential benefits. Medical Writing and Publications: Assisting in scientific writing, publication planning, and manuscript development. Regulatory Affairs: Offering guidance on regulatory submissions, compliance, and interactions with health authorities.
Keywords
Revenue
EBITDA
Valuation
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenues | $380 MM | $250 MM | $90 MM | $120 MM | $65 MM |
| Gross Profit | $190 MM | $125 MM | $45 MM | $60 MM | $32.50 MM |
| Net Income (Loss) | $43 MM | $25 MM | $9 MM | $12 MM | $6.50 MM |
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $850 MM | $720 MM | $680 MM | $650 MM | $600 MM |
| Total Liabilities | $450 MM | $400 MM | $380 MM | $350 MM | $320 MM |
| Total Equity | $400 MM | $320 MM | $300 MM | $300 MM | $280 MM |
Ratios
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
© 2026 PrivCo Holding Inc. All rights reserved.
No AI Training or Automated Data Extraction.
Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.